Minireview: computer simulations of blood pressure regulation by the renin-angiotensin system.
暂无分享,去创建一个
Hyung-Suk Kim | O. Smithies | N. Takahashi | Nobuyuki Takahashi | Oliver Smithies | Hyung-Suk Kim | J. Hagaman | John R Hagaman
[1] Helen V. Firth,et al. Down syndrome (trisomy 21) , 2005 .
[2] S. John,et al. Molecular phenotyping for analyzing subtle genetic effects in mice: Application to an angiotensinogen gene titration , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[3] B. L. Langille,et al. Maternal cardiovascular changes during pregnancy and postpartum in mice. , 2002, American journal of physiology. Heart and circulatory physiology.
[4] Y. Ohashi,et al. Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM). , 2002, Diabetes research and clinical practice.
[5] M. Marre,et al. Genetically increased angiotensin I-converting enzyme level and renal complications in the diabetic mouse , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[6] B. Brenner,et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.
[7] H. Parving,et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. , 2001, The New England journal of medicine.
[8] E. Lewis,et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. , 2001, The New England journal of medicine.
[9] J. Chan,et al. Contribution of gene polymorphisms in the renin-angiotensin system to macroangiopathy in patients with diabetic nephropathy. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[10] J. Knowles,et al. Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. , 2001, The Journal of clinical investigation.
[11] N. Chaturvedi. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. , 2001, Annals of internal medicine.
[12] G. Chatellier,et al. Prognostic value of angiotensin-I converting enzyme I/D polymorphism for nephropathy in type 1 diabetes mellitus: a prospective study. , 2001, Journal of the American Society of Nephrology : JASN.
[13] Ali G. Gharavi,et al. Molecular Mechanisms of Human Hypertension , 2001, Cell.
[14] J. Kvetny,et al. Randomized placebo-controlled trial of perindopril in normotensive, normoalbuminuric patients with type 1 diabetes mellitus. , 2001, QJM : monthly journal of the Association of Physicians.
[15] H. S. Kim,et al. Importance of quantitative genetic variations in the etiology of hypertension. , 2000, Kidney international.
[16] D. Vaughan,et al. Angiotensin-converting enzyme insertion/deletion polymorphism modulates the human in vivo metabolism of bradykinin. , 2000, Circulation.
[17] D. Ganten,et al. Regulation of renin: new evidence from cultured cells and genetically modified mice , 2000, Journal of Molecular Medicine.
[18] Bruce H. R. Wolffenbuttel,et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy , 2000, The Lancet.
[19] S. Yusuf,et al. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .
[20] D. Stec,et al. Novel mechanism of hypertension revealed by cell-specific targeting of human angiotensinogen in transgenic mice. , 1999, Physiological genomics.
[21] Hyung-Suk Kim,et al. Homeostasis in Mice with Genetically Decreased Angiotensinogen Is Primarily by an Increased Number of Renin-producing Cells* , 1999, The Journal of Biological Chemistry.
[22] M. Esler,et al. Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-II antagonism. , 1999, Journal of the American College of Cardiology.
[23] G. Heusch,et al. Infarct size reduction by AT1-receptor blockade through a signal cascade of AT2-receptor activation, bradykinin and prostaglandins in pigs. , 1998, Journal of the American College of Cardiology.
[24] J. Connell,et al. Angiotensin converting enzyme gene polymorphisms and renal disease , 1998, Current opinion in nephrology and hypertension.
[25] O. Carretero,et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. , 1997, The Journal of clinical investigation.
[26] John Quackenbush,et al. A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. , 1997, The Journal of clinical investigation.
[27] H. S. Kim,et al. Angiotensin-converting enzyme gene mutations, blood pressures, and cardiovascular homeostasis. , 1997, Hypertension.
[28] F. Cambien,et al. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study , 1996, BMJ.
[29] R. Lifton. Molecular Genetics of Human Blood Pressure Variation , 1996, Science.
[30] M. Capecchi,et al. Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. , 1996, Laboratory investigation; a journal of technical methods and pathology.
[31] J. Charles Jennette,et al. Malefemale differences in fertility and blood pressure in ACE-deficient mice , 1995, Nature.
[32] J. Hodgin,et al. A noninvasive computerized tail-cuff system for measuring blood pressure in mice. , 1995, Hypertension.
[33] H. S. Kim,et al. Genetic control of blood pressure and the angiotensinogen locus. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[34] A. Krolewski,et al. Genetic Predisposition to Diabetic Nephropathy: Evidence for a Role of the Angiotensin I–Converting Enzyme Gene , 1994, Diabetes.
[35] D. Campbell,et al. Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides. , 1994, Hypertension.
[36] F. Cambien,et al. Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. , 1994, Diabetes.
[37] Steven C. Hunt,et al. Molecular basis of human hypertension: Role of angiotensinogen , 1992, Cell.
[38] R J Jarrett,et al. Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study. , 1992, Kidney international.
[39] R. Carey,et al. Recruitment of renin gene-expressing cells in adult rat kidneys. , 1990, The American journal of physiology.
[40] P Corvol,et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. , 1990, The Journal of clinical investigation.
[41] M. Seikaly,et al. Endogenous angiotensin concentrations in specific intrarenal fluid compartments of the rat. , 1990, The Journal of clinical investigation.
[42] R. Ward. Familial aggregation and genetic epidemiology of blood pressure , 1990 .
[43] S. Kreiner,et al. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. , 1987, British medical journal.
[44] S. L. Jindal,et al. Clinical Physiology of Acid—Base and Electrolyte Disorders. , 1978 .
[45] J. Taylor. The hypertension detection and follow-up program: a progress report. , 1977, Circulation research.
[46] D. Weatherall,et al. The Principles of Human Biochemical Genetics , 1975 .
[47] J. Laragh. Hypertension manual : mechanisms, methods, management , 1974 .
[48] G. Pickering,et al. Hypertension. Definitions, natural histories and consequences. , 1972, The American journal of medicine.